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Abstract Spinal muscular atrophy (SMA) is a devastat-
ing motoneuron (MN) disorder caused by homozygous loss
of SMN1. Rarely, SMN1-deleted individuals are fully
asymptomatic despite carrying identical SMN2 copies as
their SMA III-affected siblings suggesting protection by
genetic modifiers other than SMN2. High plastin 3 (PLS3)
expression has previously been found in lymphoblastoid
cells but not in fibroblasts of asymptomatic compared to
symptomatic siblings. To find out whether PLS3 is also
upregulated in MNs of asymptomatic individuals and thus
a convincing SMA protective modifier, we generated
induced pluripotent stem cells (iPSCs) from fibroblasts of
three asymptomatic and three SMA III-affected siblings
from two families and compared these to iPSCs from a
SMA I patient and control individuals. MNs were differ-
entiated from iPSC-derived small molecule neural
precursor cells (smNPCs). All four genotype classes
showed similar capacity to differentiate into MNs at day 8.
However, SMA I-derived MN survival was significantly
decreased while SMA III- and asymptomatic-derived MN
survival was moderately reduced compared to controls at
day 27. SMN expression levels and concomitant gem
numbers broadly matched SMN2 copy number distribution;
SMA I presented the lowest levels, whereas SMA III and
asymptomatic showed similar levels. In contrast, PLS3 was
significantly upregulated in mixed MN cultures from
asymptomatic individuals pinpointing a tissue-specific
regulation. Evidence for strong PLS3 accumulation in shaft
and rim of growth cones in MN cultures from asymp-
tomatic individuals implies an important role in
neuromuscular synapse formation and maintenance. These
findings provide strong evidence that PLS3 is a genuine
SMA protective modifier.
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NSC Neural stem cell
PO Poly-L-ornithine
ROCK Rho-associated coiled-coil containing protein
kinase
SeV Sendai virus
Introduction
Proximal spinal muscular atrophy (SMA) is a usually
devastating motoneuron (MN) disorder with a broad clin-
ical variability raging from the severe type I (SMA I) with
onset in the first 6 months of life and inability to sit or walk
to the mild type III (SMA III) with onset after 18 months of
life and ability to sit and walk [1]. Autosomal-recessive
SMA is one of the most common neurodegenerative dis-
orders with an incidence of 1:6000 to 1:10,000 and a
carrier frequency of 1:35 in the Caucasian population [2,
3]. Both alleles of the disease-causing gene survival of
motor neuron 1 (SMN1) are mutated in all SMA patients
[4]. Severity and onset are mainly determined by the copy
numbers of the nearly identical SMN2 gene. Higher SMN2
copy numbers correlate with a milder phenotype [3, 5].
SMN2 is predominantly aberrantly spliced due to a single
silent variant affecting an exonic splicing enhancer. Thus,
only about 10 % of full-length SMN transcripts and protein
are generated [6, 7] from each SMN2 copy as compared to
SMN1. The ubiquitously expressed housekeeping protein
SMN is diffusely distributed in the cytoplasm and in the
nucleus where it forms distinct punctual nuclear substruc-
tures called ‘‘Gemini of coiled bodies’’ (abbreviated
‘‘gems’’) [8]. SMN plays an important role in small nuclear
ribonucleoprotein particle (snRNP) biogenesis and splicing
[9]. In addition, SMN is crucial for motoneuron develop-
ment particularly for neuromuscular junction (NMJ)
maturation and maintenance [9–11].
In less than 1 % of SMA families, homozygously
SMN1-deleted individuals are fully asymptomatic despite
carrying the same SMN2 copy number as their SMA III-
affected siblings [12, 13]. This observation suggests a
protective impact of a genetic modifier other than SMN2.
We previously identified high expression levels of plastin 3
(PLS3), an actin-binding and -bundling protein, in lym-
phoblastoid (LB) cell lines of asymptomatic but not of
symptomatic siblings using transcriptome-wide differential
expression analysis [14]. Intriguingly, PLS3, an X-linked
gene, was described not to be expressed in the
hematopoietic system but only in solid tissues [15]. This
unusual finding of high PLS3 expression in asymptomatic
individuals has further been confirmed in native blood
whereas primary fibroblasts showed identical expression
levels in both SMA III and their asymptomatic siblings
[14]. PLS3 overexpression is able to rescue axonal devel-
opment deficits in smn zebrafish morphants exhibiting axon
truncation and early branching [14, 16, 17]. Moreover,
overexpression of transgenic PLS3 in SMA mice has
shown to ameliorate all tested NMJ and MN functions
connected to F-actin dynamics. Most pronounced was the
increased neuronal connectivity and delayed axonal prun-
ing in PLS3 overexpressing SMA mice. Moreover the
proprioceptive input on MN somata was restored in PLS3
overexpressing SMA mice in comparison to SMA mice.
Thus, high PLS3 levels restore impaired MN and NMJ
functions caused by reduced SMN levels [18]. In contrast,
overall survival rate is only very moderately prolonged in
this severe SMA mouse model owing to impairment of
other organs such as heart, lung and intestine [18].
The major questions that we aimed to address in this
study are: (1) Is PLS3 indeed elevated in MN cultures of
asymptomatic individuals versus SMA III patients and thus
a genuine SMA modifier candidate? (2) Does PLS3 influ-
ence the expression level of SMN in MNs? (3) Which
phenotype do asymptomatic MNs exhibit versus SMA III
MNs versus MNs of SMA I and control individuals?
Given the inaccessibility of human spinal MNs as main
target tissue of SMA, we used induced pluripotent stem cell
(iPSC) technology [19, 20] to shed light on these three
questions. Somatic human donor cells were converted into
a pluripotent state by ectopic overexpression of four tran-
scription factors (4F) of the pluripotency regulatory circuit
described by the team of Yamanaka [21]. Mimicking
human embryogenesis and neural development, human
iPSCs can be redifferentiated into spinal MNs by pattern-
ing with the morphogens retinoic acid (RA) for
posteriorization and sonic hedgehog (SHH) for ventral-
ization [22]. Several protocols have been established for
the controlled derivation of MN cultures from human
pluripotent stem cells [23–29]. Previously, a cellular
in vitro SMA model was established from a SMA I patient
displaying essential features of in vivo SMA pathology
such as reduced SMN expression and gem numbers, and
impeded MN survival rate [23].
We established a personalised in vitro SMA III disease
model of PLS3 discordant families to elucidate PLS3 mode
of action in SMA III. In total, adult fibroblasts of three
asymptomatic individuals and three SMA III siblings from
two PLS3 discordant families, one SMA I patient and five
healthy control individuals were reprogrammed by either
retrovirus or Sendai virus (SeV) mediated 4F overexpres-
sion and thoroughly validated. Subsequently, a neural
progenitor cell population (smNPCs, small molecule neural
precursor cells) [30] was generated by a small molecule-
based protocol and subsequently differentiated into MNs.
In four phenotypic groups (controls, SMA I and PLS3
discordant SMA III and asymptomatic siblings), SMA
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disease-related features (MN survival, gem numbers, and
SMN expression on RNA and protein levels), growth cone
architecture and PLS3 expression were analysed during
MN development in order to recapitulate SMA pathology
and to understand potential protective mechanisms.
Materials and methods
Patients’ material
Fibroblast cell lines were established from skin biopsies of
three SMA III patients and three asymptomatic siblings
overexpressing PLS3 who belong to two SMA discordant
families (Fig. 1a and Online Resource Tab. S1) [12, 14,
31]. In addition, iPCS lines reprogrammed from fibroblasts
of an independent SMA I patient [32] and five unrelated
control individuals (Online Resource Tab. S1; [33]) were
used. Informed written consent was obtained from all
patients or care givers according to the Declaration of
Helsinki, and the study was approved by the ethics com-
mittee of the University Hospital of Cologne.
Generation of iPSCs
Retroviral vectors harbouring SOX2, OCT4, KLF4 and
c-MYC [21] were used to generate iPSC lines HGK1
(SMA I) [32], and discordant family 1 members SMA III
(HGK13) and asymptomatic (HGK16) by iPierian (South
San Francisco, CA, USA). Discordant family 2 iPSC lines
from two asymptomatic (HGK21 and HGK28) and two
SMA III (HGK22 and HGK27) patients were generated
with Sendai virus (SeV) vectors supplied by ID Pharma Co.
Ltd (formerly DNAVEC Corporation) [34]. In case of
family 2, two independent iPSC clones from each of the
four siblings were used in all experiments. In brief, primary
fibroblasts were centrifuged for 45 min at 32 C with
1500 g (spinfection) and cultivated in Advanced DMEM
containing 5 % foetal calf serum (FCS) and 1 % Glu-
taMAXTM (all from Life Technologies) (modified method
from [35]). Five days post-infection (d5), SeV infected
fibroblasts were trypsinized and seeded onto feeder-coated
dishes in DMEM/F-12 containing 10 % knockout serum
replacement, 1 % nonessential amino acids (NEAA), 1 %
GlutaMAXTM, 1 % pyruvate, 0.1 mM b-mercaptoethanol
and 6–10 ng/mL basic fibroblast growth factor (bFGF) (all
from Life Technologies). Medium was changed every other
day until clonal iPSC colonies were manually picked.
Cell culture of human iPSCs
Human iPSC lines were subsequently grown on MatrigelTM
(MG)-coated cell culture plates in mTeSRTM1 medium
(STEMCELL Technologies) with daily medium change.
iPSCs were split by Alfazyme (PAA) treatment when cul-
tures were 70–75 % confluent. Medium was supplemented
with 10 lM ROCK inhibitor Y-27632 (Tocris Bioscience)
post plating to promote single cell survival [36].
DNA extraction and whole-genome karyotyping
in iPSCs
Genomic DNA (gDNA) of iPSCs was isolated with
DNeasy Blood and Tissue Kit (Qiagen) according to
manufacturer’s instructions. Whole-genome single
nucleotide polymorphism (SNP) genotyping was con-
ducted for HGK13 and HGK16 at the Cologne Centre of
Genomics (University of Cologne) using the Affymetrix
Genome-Wide Human SNP Array 6.0 (Affymetrix). All
other iPSC lines were processed with an Illumina
Human610-Quad chip or a HumanCytoSNP-12 chip at the
Institute of Human Genetics, University of Bonn. Data
analysis was performed with IlluminaBeadStudio.
Isolation of RNA and quantitative real-time
RT-PCR (qRT-PCR)
Total RNA was extracted with RNeasy Blood and Tissue
Kit with parallel DNase I treatment (Qiagen) according to
manufacturer’s instructions. Reverse transcription into
cDNA was carried out by QuantiTect Reverse Transcrip-
tion Kit (Qiagen) or iScriptTM Kit (Bio-Rad) according to
manufacturers’ instructions. All qRT-PCRs were per-
formed with LightCycler 1.5 instrument using Fast Start
DNA Master SYBR Green I Kit (Roche). All primer
sequences are listed in Online Resource Tab. S2.
Retroviral transgene silencing by semi-quantitative
reverse transcription (RT)-PCR
Total RNA was isolated using TRIzol (Life Technologies)
or RNeasy Mini Kit (Qiagen). Reverse transcription was
carried out with the iScript Kit (BioRad) plus DNase I
(Promega) according to the manufacturer’s manual. qRT-
PCR was performed using the iCycler (BioRad) applying
standard protocols as outlined previously [32]. All results
were normalised to GAPDH. PCR samples were analysed
by agarose gel electrophoresis with 1.2 % agarose gels
supplemented with 0.1 lL ethidium bromide per mL gel in
TAE buffer.
Undirected differentiation of iPSCs into three germ
layers
To induce spontaneous differentiation, human iPSC colo-
nies were detached by collagenase (1 mg/mL) treatment
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and transferred to non-adhesive Petri dishes in knockout-
DMEM containing 20 % knockout serum replacement,
1 % NEAA and 1 % GlutaMAXTM to induce embryoid
body (EB) formation. After 6 days, EBs were plated onto
gelatine-coated dishes in DMEM containing 10 % FCS,
1 % pyruvate and 1 % NEAA for further differentiation
into meso- and endodermal or neuroectodermal lineages.
Cells were cultured for further 10 days and subsequent
immunocytochemical analysis [37].
Teratoma formation
To test ability of teratoma formation, 1 9 106 iPSCs were
resuspended as clumps in PBS and injected into the tes-
ticular capsule of immune-compromised SCID/Beige mice.
After 8–10 weeks, tumours were isolated, fixed using 4 %
paraformaldehyde (PFA) and immunohistologically anal-
ysed by haematoxylin/eosin staining.
Western blot analysis
Whole cell lysates were sampled with radio-immunopre-
cipitation assay (RIPA) buffer (Sigma–Aldrich). SDS-
PAGE (Tris-HCl) and subsequent wet blotting were per-
formed according to standard protocols. The following
primary antibodies were used: mouse anti b-actin
(1:60,000, Sigma–Aldrich), mouse anti-SMN (1:100,
immunoGlobe) and rabbit anti-PLS3 (1:50; [14]) (Online
Resource Tab. S3).
PLS3 siRNA knock-down
Predesigned negative siRNA (Cat: 1022076) and PLS3
siRNA (Cat: SI03174136) were purchased from Qiagen.
Control and PLS3 siRNA stocks were prepared according
to manufacturer’s instructions. 2 9 105 cells were seed
into a six-well plate 1 day prior to transfection. 50 pmol
of siRNA and 4l of DharmaFECT 1 transfection reagent
(Cat: T-2001-01, GE Life Science) were diluted in Opti-
MEM (Cat: 31985-070, Life Science) according to
manufacturer’s instruction and used for the knockdown
experiment. Glioblastoma cells (U373) were transfected
with non-silencing negative control and PLS3 siRNAs.
After 6 h of transfection, the medium was changed and
cells were incubated at 37 C for 48 h. The efficiency of
the knockdown experiment was verified by Western
blotting.
Generation and cultivation of small molecule neural
precursor cells (smNPCs)
Generation and cultivation of smNPCs was performed as
described [30]. Briefly, iPSC colonies were detached by
collagenase treatment and transferred to a non-adherent
Petri dish in knockout-DMEM containing 20 % knockout
serum replacement, 1 % NEAA, 1 % GlutaMAXTM, 1 mM
b-mercaptoethanol, 10 lM ROCK inhibitor Y-27632
(Merck), 0.5 lM LDN193189 (Axon MedChem), 10 lM
SB431542 (Sigma–Aldrich), 0.5 lM purmorphamine (Pur)
(Merck) and 3 lM CHIR99021 (Stemgent) (adapted from
[30] ). After 2 days, medium was changed to medium
without Y-27632. On d4 of culture, dual SMAD signalling
inhibition was stopped by withdrawing LDN193189 and
SB431542. Finally, EB-like spheres were collected and
mildly chopped by trituration. Spherical fragments were
plated on MG-coated dishes in 1:1 DMEM/F-12:Neu-
robasal medium containing 0.5 % N2 Supplement, 0.5 %
GlutaMAXTM, 1 % B27 supplement minus vitamin A
(B27-RA) (all Life Technologies) supplemented with
10 lM ROCK inhibitor Y-27632, 150 lM L-ascorbic-acid-
2-phosphat (LAAP) (Sigma–Aldrich), 0.5 lM Pur and
3 lM CHIR99021. After five passages, medium for stably
bFig. 1 Determination of MN numbers by HB9 and ISL1 immuno-
cytochemical staining in mixed MN cultures. a Pedigrees of SMA
discordant families 1 and 2 (grey symbols asymptomatic; black
symbols SMA III; white symbols healthy carriers). Subordinated
tables provided SMN1/SMN2 copy numbers, PLS3 expression levels
in lymphoblastoid cells and current age. Age of onset in HGK13 was
13 months, in HGK27 13 years and in HGK22 18 years. b Semi-
quantitative RT-PCR of PLS3 and HPRT (used for equal loading
control) from RNA isolated from lymphoblastoid cell lines of family
1 and 2. c Representative staining from motoneuron-differentiated
smNPC lines from each of the four phenotypes (control, SMA I, SMA
III and asymptomatic) demonstrated strong expression of MN
markers HB9 and ISL1 (green) or neuronal marker SMI-32 (green)
on d8 irrespective of their genetic background. PLS3 (red) was also
expressed in HB9? MNs. d Survival of MNs at d27 showed clear
differences. In SMA I hardly any ISL1? (green) or HB9? (green)/
ChAT? (red) MNs were seen in contrast to control, SMA III and
asymptomatic lines. SMI-32 expression was detectable in all four cell
lines. Insets depict corresponding pictures with stained nuclei. Nuclei
were counterstained with DAPI (blue). Scale bars 100 lm, valid for
all images. e Grouping HB9? or ISL1? MN numbers according to the
four phenotypes did not present any statistically significant difference
on d8 in SMA I and SMA III. Only asymptomatic revealed an initially
lower MN number. f On d27, all four groups lost HB9? MNs in
comparison to d8 (healthy control 29.8 to 24.8 %; SMA I 26.8 to
0.7 %; SMA III 20.3 to 7.4 %; asymptomatic 16.5 to 5.5 %).
Determination of ISL1? neurons revealed a similar tendency.
Between d8 and d27, massive death of ISL1? MNs was only
detectable in SMA I phenotype (19.5 to 2.3 %) whereas the
discordant family members exhibited a moderate decline in ISL1?
cell numbers (SMA III 21.5 to 13.9 %; asymptomatic: 11.8 to 6.8 %).
Healthy controls even gained a small percentage of ISL1? MNs (21.2
to 24.6 %). For d8, results showed the MN counting relative to the
total number of cells from two to three independent differentiation
experiments. For d27, two to three independent differentiation
experiments were considered. Mean ratios were computed relative
to total number of cells in case of HB9 and total number of b III-
tubulin? neurons in case of ISL1, respectively. Error bars repre-
sented ± SEM of two to three independent differentiation
experiments. Significance was calculated relative to grouped five
healthy controls (Kruskal–Wallis test with Dunn’s post hoc test,
p\ 0.05 = *, p\ 0.01 = **, p\ 0.001 = ***)
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growing smNPC lines was switched to standard medium
(1:1 Advanced DMEM/F-12:Neurobasal medium con-
taining 1 % N2 Supplement, 1 % GlutaMAXTM, 2 % B27-
RA (all Life Technologies), 5 lg/mL bovine serum albu-
min (BSA) (Carl Roth) supplemented with 150 lM LAAP,
1 lM Pur and 3 lM CHIR99021). Regular splitting was
carried out by Accutase (PAA) treatment in a ratio of
1:8–1:12 in previous standard medium which was changed
every other day.
Motoneuronal differentiation from smNPCs
Based on the original protocol [30], a modified MN dif-
ferentiation protocol was developed. In order to pre-
pattern smNPCs towards a ventral-caudal fate, 1 lM
retinoic acid (RA) (Sigma–Aldrich) and 1 lM smooth-
ened agonist (SAG) (Calbiochem) were added to standard
smNPC medium with daily medium change for at least
2 weeks. To differentiate smNPCs into MNs, smNPCs
were seeded onto 6-well plates coated with 15 lg/mL
poly-L-ornithine/10 lg/mL laminin (PO/Ln) in standard
smNPC medium. Once cells reached 70 % confluence,
medium was changed to 1:1 Advanced DMEM/F-
12:Neurobasal medium containing 1 % N2 Supplement,
1 % GlutaMAXTM, 2 % B27-RA, 5 lg/mL BSA supple-
mented with 150 lM LAAP, 1 lM Pur, 1 lM RA and
1 lM SAG initiating motoneuronal patterning for the next
7 days. On d7 of differentiation, cells were singularised
by alfazyme treatment (5–7 min, 37 C). Bigger cell
clumps were retained by a cell strainer (40 lm). For final
maturation during the following weeks, 150,000 single
cells per well of a chamber slide (Millipore) coated with
PO/Ln and 5 lg/mL fibronectin (Fn) were plated in
maturation medium containing Neurobasal medium, 1 %
N2 Supplement, 1 % GlutaMAXTM, 1 % NEAA, 2 %
B27-RA plus 10 lM ROCK inhibitor Y-27632, 10 ng/mL
brain-derived neurotrophic factor (BDNF), 10 ng/mL glial
cell line-derived neurotrophic factor (GDNF), 10 ng/mL
insulin-like growth factor 1 (IGF-1) (all R&D System),
0.2 mM LAAP and 500 lM dibutyryladenosine cyclic
monophosphate (db-cAMP) (Enzo Life Sciences). At least
two million cells were seeded per 3.5 cm-dish (PO/Ln/Fn-
coated) for later RNA or protein harvest. Medium was
changed the next day. To thrust neural progenitor cells
into neuronal differentiation, 10 lM Notch-signalling
pathway inhibitor DAPT (Sigma–Aldrich) was added
from d8 to d12 [38, 39]. Moreover, 0.5 lM Pur and
50 nM RA were supplemented from d8 to d15 to ensure
proper maturation of potentially present pMN-patterned
progenitor cells [27, 29]. Maturation medium was chan-
ged every other day. MNs were maturated until d27 for
3 weeks (i.e., 21 days) in total.
Immunocytochemistry
Cells were fixed with 4 % PFA in 1 9 phosphate buffered
saline (PBS) for 10 min at room temperature and blocked
in 10 % FCS in Hank’s buffered salt solution (HBSS)
containing Ca2?/Mg2? (Life Technologies). Primary anti-
bodies were administered over-night in 5 % FCS in HBSS.
After washing three times with HBSS, samples were
incubated with the secondary antibodies in 5 % FCS in
HBSS at room temperature for 1 h. For visualisation of the
actin cytoskeleton in growth cones, samples were incu-
bated with phalloidin conjugated with Alexa555 in 5 %
FCS in HBSS at room temperature for 1 h. If necessary,
staining solutions were additionally supplemented with
0.1 % Triton X-100 (Sigma–Aldrich). Nuclei were coun-
terstained with 4’,6-diamidino-2-phenylindole (DAPI) and
samples were mounted with Mowiol 4–88 mounting solu-
tion (Carl Roth). Pictures were taken with an
AxioCamMRn and further processed with Axiovision
software (Zeiss). Confocal laser scanning microscopy was
performed using Zeiss Meta 510 microscope. Pictures were
processed with ZEN software and further analysed with
ImageJ and Fiji software. Information about primary and
respective secondary antibodies is given in Online
Resource Tab. S3.
For quantitative analysis, 7–10 pictures were randomly
chosen. In each image section, the total number of vital
cells was ascertained by counting DAPI? nuclei or b III-
tubulin? neurons, respectively. Then, the epitope of inter-
est was quantified to compute the ratio of positive cells
relative to the numbers of total cells or total neurons (d8:
HB9: 500–2000 cells; ISL1: 600–2400 cells in total; d27:
HB9: 400–1900 cells; ISL1: 300–900 neurons in total). In
MN cultures (d27) counting was performed in areas where
it was feasible.
For gem quantification, gems and total numbers of
nuclei were counted to further calculate their ratio.
Fibroblasts: 150–300 cells in total; iPSCs: 950–1300 cells
in total; smNPCs: 1200–1700 cells in total; MN cultures:
200–450 cells (d8) and 300–550 cells (d27) in total.
Statistical analyses
Counting from immunocytochemical stainings and
expression rates from molecular-biological experiments
were expressed as mean values ± SEM. All data were
analysed by Kruskal–Wallis non-parametric test with
Dunn’s post hoc correction for multiple comparisons.
Statistical significance of measurements was determined by
GraphPad Prism software. Differences were considered
significant when p\ 0.05. Statistical significance was
calculated relative to control line 30 m-r12 (when plotting
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individual cell lines) or grouped five healthy control lines
(when plotting phenotype groups), respectively.
Results
SMA discordant families
All individuals included in this study except for the con-
trols showed homozygous deletions of SMN1 and were
expected to develop SMA based on SMN2 copy number
and current age [4, 13]. However, three females were fully
asymptomatic despite carrying only three SMN2 copies as
their affected male siblings (Fig. 1a and Online Resource
Tab. S1) [12, 14, 31]. The three asymptomatic siblings
showed increased PLS3 levels in lymphoblastoid cell lines
(Fig. 1b and [14]) but not in fibroblasts compared to their
affected siblings (Fig. 2a and [14]), implying a protective
role of PLS3 concerning SMA. Similar results were found
in five further SMA discordant families [14].
Generation and characterisation of iPSC lines
from individuals of SMA discordant families
Human fibroblast cell lines of SMA discordant family 1
comprising an asymptomatic sibling (ML101) and an SMA
III patient (ML102) as well as of an independent SMA I
patient (ML17) [32] were reprogrammed by retroviral
infection via pMXs-based vectors with the classical four
Yamanaka factors (4F: OCT4, SOX2, KLF4, c-MYC) [19,
21] at iPierian Inc. (San Francisco, USA). One clone per
line was delivered. Similarly, healthy unrelated control
lines 30 m-r12 [33] and 35 m-r1 were generated and fully
characterised previously. Additionally, non-integrating
Sendai virus (SeV) vector system containing 4F [40] was
employed to reprogram human fibroblast cell lines from
SMA discordant family 2 (asymptomatic ML11 and ML13
and SMA III patients ML12 and ML14) (Fig. 1a and
Online Resource Tab. S1). Two independent clones for
each of the four siblings belonging to family 2 were
selected, validated and used in all experiments. In addition,
unrelated healthy control cell lines 51f-s6, 61f-s2 and
62 m-s4 were generated and validated in the same manner
(Online Resource Tab. S1).
Representative iPSC lines clearly demonstrated human
ESC-like morphology and characteristics including a small
cell body with high nucleus/cytoplasm ratio, flat growth,
typical colony shape, activity of alkaline phosphatase (AP)
[21, 41] and expression of specific surface antigens (e.g.,
SSEA-3, SSEA-4, TRA-1-60, TRA-1-81) as pluripotency
markers [41] (Online Resource Fig. S1A).
By SNP-array analysis, all new iPSC lines were scruti-
nised for any potential genomic aberration (Online
Resource Fig. S1B and Tab. S1). If the genomic variant
occurred in all iPSC clones and the original fibroblast cell
line, the variant was regarded as an inherited intrinsic
feature of this individual cell line already present in the
donor genome. All iPSC lines applied in this study were
genomically intact according to SNP-array analysis.
Assessment of SeV nucleocapsid protein NP expression
via semi-qRT-PCR [42] proved loss of SeV vector activity
in SeV-derived iPSC lines at later passages ([p7) (Online
Resource Fig. S1C and Tab. S1). Human iPSC lines gen-
erated by retrovirus transduction were successfully
examined for proviral transgene silencing (Online
Resource Tab. S1).
To test the developmental potential of pluripotent SCs
in vitro, iPSC colonies were grown in suspension as
embryoid bodies (EBs). Upon withdrawal of pluripotency-
maintaining growth factors, iPSCs spontaneously com-
menced to differentiate into cells of all three germ layers
within those EBs [37]. When plated and immunocyto-
chemically analysed after further growth, representative
iPSC lines exhibited presence of tissue of endodermal (a-
fetoprotein, AFP), mesodermal (smooth muscle actin,
SMA) and neuroectodermal origin (b III-tubulin) (Online
Resource Fig. S2A and Tab. S1).
We further verified pluripotency in human iPSCs by the
teratoma formation assay [41]. All tested human iPSC lines
formed tissues of the three germ layer lineages displaying
adenoid goblet cell-like cells (endodermal tissue), cartilage
(mesodermal tissue) and neural rosettes (ectodermal tissue)
(Online Resource Fig. S2B and Tab. S1).
iPSCs give rise to stably expandable self-renewing
neural precursor population of smNPCs
The establishment of stably expandable fully patternable
neural progenitor cell population comprised the advantage
to monitor the entire developmental process of MN gen-
eration in vitro: this enables to examine possible PLS3-
mediated changes in different cell populations of an in vitro
SMA cell culture model from original fibroblasts via iPSCs
to NPCs and ultimately to MN cultures. Recently, a novel
neural precursor cell type (smNPCs) was introduced with
the advantageous feature of robust cost-effective prolifer-
ation and solid MN differentiation capability [30]. All 16
iPSC lines were converted into corresponding smNPC lines
expressing CNS neural stem cell (NSC) markers like
SOX1, SOX2, nestin and PAX6 as well as the early NSC
marker FORSE-1 (Online Resource Fig. S3). By default,
smNPCs comprise an early pre-rosette NPC population
[30]. Hence, expression of classical rosette-markers PLZF
and ZO-1 did not reveal the typical petal-shape arrange-
ments with centred ZO-1 accumulation (Online Resource
Fig. S3) further confirming smNPC identity [30].
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Motoneuronal differentiation of smNPCs revealed
a SMA phenotype
All smNPC lines were subjected to a modified differenti-
ation regimen adapted from the original protocol [30].
Upon administration of RA and SAG in the smNPC culture
medium, smNPCs were pre-patterned towards MN
precursor fate for at least 2 weeks. Then, smNPCs under-
went regular patterning for 1 week (d0–d6). On d7 of
differentiation, cells were singularised and seeded for final
maturation.
Immunocytochemical labelling of patterned smNPCs on
d8 confirmed expression of classical markers of pMN-do-
main precursors such as OLIG2 and NKX6.1 [22] (Online
Fig. 2 Determination of number of SMN containing gems in the four
phenotype classes throughout reprogramming and MN differentiation.
a Immunocytochemical staining of cell lines representing the four
phenotype classes in different cell populations during in vitro MN
development. Principally, SMN (green) was either diffusely spread in
the cytoplasm or visible as distinct dot-like nuclear accumulations,
i.e., gems (arrows). Nuclei were counterstained with DAPI (blue).
Dashed line enclosed area magnified in insets (scale bar 20 lm, valid
for all images). b Overview of gem number quantification in different
cell populations among four phenotypic classes. Overt SMN
deficiency in SMA I resulted in poor gem formation and highly
significant gem number reduction compared to control. However,
more SMN2 copies (3–4) in SMA III visibly led to a medium gem
number relative to control. Notably, asymptomatic siblings shared
almost equal gem numbers with their SMA III-affected brothers.
Error bars represented ± SEM of duplicates in fibroblasts (n = 2)
and triplicates in iPSCs and smNPCs (n = 3). MN cultures displayed
data of two to three independent MN differentiation experiments.
Significance was calculated relative to grouped two healthy controls
(fibroblasts, iPSCs, smNPCs) and to grouped five healthy controls
(MN culture d8 and d27), respectively (Kruskal–Wallis test,
p\ 0.05 = *, p\ 0.01 = **, p\ 0.001 = ***)
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Resource Fig. S4). Motoneuron-differentiated smNPC lines
exhibited robust expression of pan-NSC markers SOX2
and nestin [43, 44] while early CNS marker PAX6 [45] was
moderately expressed (Online Resource Fig. S4). Sufficient
posteriorization was confirmed by broad presence of
HOXB4 [29]. In addition, OLIG2?/NKX6.1? double pos-
itive precursors indicated correct ventral pMN-
regionalisation [22]. Finally, low expression of NKX2.2, a
marker of the most ventral neural tube progenitor domain
p3, disclosed an exact hit of the desired pMN domain
confirming the shift of originally anterior smNPCs into the
ventral-posterior pMN domain.
Classical MN markers HB9 and ISL1 and the neuronal
marker SMI-32 [22] showed strong expression in all four
phenotype classes (control, SMA I, SMA III, asymptomatic)
in smNPC-derivedMN cultures on d8 (Fig. 1c). Irrespective
of their genetic background, representative cell lines largely
exhibited ISL1?/b III-tubulin? MNs as well as SMI-32?
neurons. Furthermore, HB9?MNs showed detectable PLS3
expression strongly suggesting that this in vitro disease
model is suitable for further studies on PLS3-specific
influence in SMA discordant families (Fig. 1c).
Numbers of HB9? MNs ranged highest in healthy
controls (29.8 %) closely followed by SMA I (27.2 %)
(Fig. 1d). Discordant family members showed fewer HB9?
MN in SMA III (20.3 %) and asymptomatic lines (16.5 %).
Similarly, higher number of ISL1? MNs were present in
controls (21.2 %), SMA I (19.5 %) and SMA III (21.5 %),
while asymptomatic individuals showed a lower number of
ISL1? MNs (11.8 %). Significant differences in MN
numbers among phenotype classes were found only
between control and asymptomatic on d8 (Fig. 1e). MN
numbers for each individual cell line and corresponding
phenotype groups are given in Online Resource Figs. S5A-
S5B. Notably, SMA I line demonstrated high MN numbers
on d8 suggesting that MN generation per se is not impaired
by SMN reduction.
The detrimental effect of SMN loss in MN maintenance
became obvious after 3 weeks of further maturation
(Fig. 1d). On d27, MN cultures were again immunocyto-
chemically stained for MN markers HB9, ISL1, neuronal
marker SMI-32 and mature MN marker ChAT in addition.
SMA I line hardly contained any HB9? (0.7 %) or ISL1?
(2.3 %)MNs, respectively, however SMI-32? neurons were
detected (Fig. 1d). In contrast, SMA III and asymptomatic as
well as control MNs clearly expressed all aforementioned
MN markers. Yet, in comparison to d8 SMA III and
asymptomatic MN cultures at d27 exhibited a distinct
decline of MN number (Fig. 1f). Quantification unravelled a
very significant loss of HB9? and ISL1? MNs in SMA I
compared to control and an intermediate loss in SMA III and
asymptomatic on d27 (Fig. 1f). Quantification of MNs in
individual cell lines is given in Online Resource Fig. S5C–D.
In summary, we established an in vitro SMA model of
mild SMA III and asymptomatic siblings based on iPSC-
differentiation reflecting progressive MN loss in regard to
disease severity on d27: A strong reduction in MN numbers
was observed in SMA I and a moderate decline in SMA III
and asymptomatic individuals on d27. However, no sig-
nificant difference between SMA III and asymptomatic
siblings was found suggesting that the protective effect is
not related to the capacity to develop and maintain MNs.
Number of gems correlated with SMN2 copy
numbers in phenotype classes throughout MN
differentiation
As a sign of SMA pathology, loss of gems correlates with
low SMN expression in SMA patients [46]. Consequently,
gem numbers were determined in all cell populations of
every donor fibroblast line, iPSC lines and their derived
smNPC lines and differentiated MN cultures on d8 and
d27. Immunocytochemical staining of SMN in the four
phenotypic classes demonstrated a diffuse SMN dispersion
in the cytoplasm. On the other hand, there were gems
present as distinct nuclear agglomerations. Healthy control
fibroblast line 30 m and the derived iPSC line 30 m-r12
showed the highest gem numbers in all cell populations
(Fig. 3a). In contrast, SMA I fibroblast line ML17 and
derivative line HGK1 consistently lacked visible gems.
SMA III and asymptomatic lines, however, revealed gems
in all cell populations (Fig. 3a). When quantified, the
overview of phenotypes illustrated a recurring distribution
pattern throughout the different cell populations during
MN development (Fig. 3b). Compared to control, gem
numbers in SMA I were highly diminished whereas SMA
III and asymptomatic were intermediately reduced in
comparison to controls (Fig. 3b). While adult somatic cells
(i.e., fibroblasts) indicated the overall highest gem numbers
among the phenotype classes rapidly proliferating cell
populations (iPSCs and smNPCs) revealed the fewest gem
numbers in general. However, once subjected to MN dif-
ferentiation, total gem numbers increased within all
phenotype groups exhibiting statistically significant
reduction in SMA I, SMA III and asymptomatic compared
to controls (Fig. 3b). Quantification of gems in each cell
line and respective phenotype groups is depicted in Online
Resource Fig. S6.
PLS3 was highly upregulated in mixed MN cultures
of asymptomatic individuals while SMN showed
similar expression levels in discordant siblings
A cornerstone of SMA pathology in SMN1-deleted indi-
viduals is low SMN expression which was already
demonstrated in iPSC-derived SMA I models [23, 47].
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Therefore, SMN and PLS3 mRNA expression were exam-
ined by qRT-PCR while SMN and PLS3 protein amounts
were assessed by semi-quantitative Western blotting.
SMN mRNA amount was markedly diminished in SMA
I compared to control in all cell populations. SMA III and
asymptomatic siblings exhibited similar SMN expression in
fibroblasts, iPSCs or smNPCs and reached only moderate
expression levels in comparison to controls (Online
Resource Fig. S7A–E).
PLS3 mRNA expression was more variable. In fibrob-
lasts, the four phenotype classes expressed low and equal
PLS3 levels (Online Resource Fig. S8A–E). Contrarily, in
strongly proliferating cell populations like iPSCs and
smNPCs PLS3 expression was overall higher. Asymp-
tomatic individuals ranged always at the highest PLS3
expression level in comparison to their affected siblings
although at a statistical non-significant level (Online
Resource Fig. S8A–E). SMA I and SMA III instead
exhibited a lower PLS3 expression in mixed MN cultures
in comparison to iPSCs and smNPCs. Most importantly,
the asymptomatic group significantly upregulated PLS3
expression by 4.8-fold in mixed MN cultures compared to
total controls (Online Resource Fig. S8A–E), by 6.2-fold
compared to male controls and 3.5-fold compared to
female controls separately. Healthy controls 35 m-r1,
30 m-r12 and 62 m-s4 showed low PLS3 expression upon
MN differentiation delivering the least PLS3 amount
(Online Resource Fig. S11A).
Next, we analysed the SMN and PLS3 protein expres-
sion in the four phenotypic groups and respective four cell
populations. SMN protein levels resembled SMN mRNA
expression in the four cell populations (Fig. 2a–d). In SMA
Fig. 3 Overview of SMN and PLS3 protein expression during
in vitro MN development. a–d Representative immunoblots from
fibroblasts (a), iPSCs (b), smNPCs (c) and MN cultures (d) of all four
phenotypes (control, SMA I, SMA III and asymptomatic) stained with
antibodies against PLS3 and SMN. Actin was used as equal loading
control. (e, f) Quantification of SMN and PLS3 protein relative to b-
actin levels. In fibroblasts, iPSCs and smNPCs error bars
represented ± SEM of duplicates (n = 2). MN culture (d27) dis-
played data of two to three independent MN differentiation
experiments. Significance was calculated relative to grouped two
healthy controls (fibroblasts, iPSCs, smNPCs) and to grouped five
healthy controls (MN culture d27), respectively (Kruskal–Wallis test,
p\ 0.05 = *, p\ 0.01 = **, p\ 0.0001 = ****)
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I cells the SMN level was visibly reduced and always the
lowest among the four phenotypes (Fig. 2a–e and Online
Resource Fig. S9A–D). SMN expression was comparable
between SMA III and asymptomatic siblings and only
insignificantly reduced as compared to control. In MN
cultures, SMA III and asymptomatic siblings exhibited
slightly higher but insignificant elevated SMN expression
than control levels. This data excludes SMN levels as the
reason for SMA protection in asymptomatic siblings.
Phenotypic grouping demonstrated a general low SMN
expression rate in adult fibroblasts in which SMN amounts
in SMA I was visibly lower compared to control, SMA III
and asymptomatic. Highly proliferative iPSCs and
smNPCs presented a globally higher SMN expression rate
(Fig. 2e).
Unlike SMN expression, PLS3 protein showed a more
diverse expression pattern among different cell populations
as well as among phenotype groups. In fibroblasts, an
almost equal PLS3 expression rate was detected in all
phenotype groups (Fig. 2a and Online Resource
Fig. S10A). Probing protein samples from iPSCs, smNPCs
and MN cultures with anti-PLS3 antibody during
immunoblotting demonstrated two bands around the
assumed size of 70 kDa. (Figure 2b). PLS3 in vitro siRNA-
mediated knock-down identified the upper band as the
correct specific PLS3 signal (Online Resource Fig. S11C).
In iPSCs and smNPCs, PLS3 expression varied among
individuals without presenting any significant difference
among the four groups. However, the asymptomatic sib-
lings showed a tendency of higher PLS3 expression in
iPSCs and smNPCs than their SMAIII-affected siblings in
both SMA discordant families (Fig. 2f and Online
Resource Fig. S10B–C). Most importantly, in mixed MN
cultures asymptomatic siblings showed highly significant
upregulation of PLS3 expression as compared to total
controls (Fig. 2d, f and Online Resource Fig. S10D).
Moreover, PLS3 levels in asymptomatic exceeded those of
their SMA III-affected siblings by 1.7-fold. Taking family
2 separately, the increase in PLS3 in asymptomatic indi-
viduals was 1.9-fold as compared to SMA III symptomatic
and highly consistent between two different clones for each
of the four siblings. Instead, asymptomatic line HGK16
from family 1 did not display a significant PLS3 upregu-
lation in our MN culture model, although the level was
clearly elevated in both iPSCs and smNPC as compared to
the affected sibling HGK13. Since only one clone was
available from this line, we could not verify the result in an
independent clone.
PLS3 expression in male and female controls was,
consistent with the RNA expression, strikingly low and did
not differ between genders. However, at single individual
level differences were seen (Online Resource Fig. S11A,
B).
Comparison of the PLS3 expression levels among the
four cell populations revealed a low and equal expression
in fibroblasts while an increased expression in iPSCs and
smNPCs was detectable with no significant differences
between the groups. Instead, mixed MN cultures showed a
highly significant PLS3 upregulation in asymptomatic
compared to total controls (Fig. 2f).
These results demonstrated that PLS3 is indeed specif-
ically upregulated in mixed MN cultures of asymptomatic
as compared to SMA III siblings and controls advocating
the role of PLS3 as genuine protective modifier in SMA.
PLS3 is abundant in growth cones of asymptomatic
MN cultures
Originally it was reported that endogenous PLS3 accu-
mulates in F-actin rich growth cones of primary murine
MNs [14]. It is being discussed that PLS3 exerts a pro-
tective effect in stabilising neuromuscular connectivity and
improved MN-synapse architecture as demonstrated in a
PLS3 overexpressing mouse model [18]. Therefore, triple
immunocytochemical staining of axonal marker micro-
tubule-associated protein tau (MAPT), PLS3 and actin was
performed in MN cultures on d27. Subsequently, cellular
distribution was examined in growth cones by confocal
laser scanning microscopy. MAPT? axonal protrusions
ended in cones with very delicate thin branches containing
PLS3 and actin (Fig. 4a–c and Online Resource
Fig. S12A). In controls, PLS3 and actin appeared evenly
distributed and co-localised (Fig. 4a). SMA III lines dis-
played a more separate PLS3 and actin distribution in the
growth cone (Fig. 4b). On the other hand, asymptomatic
lines showed strong PLS3 expression in axon rods and
growth cone centre while actin accumulated at the rims
(Fig. 4c). Growth cone area size was determined by bor-
dering each growth cone individually. Averaged area size
was enlarged in SMA III and asymptomatic compared to
control (Online Resource Fig. S12B). Merged pictures
revealed co-localisation of PLS3 and actin in growth cones
of control, SMA III and asymptomatic in iPSCs derived
mixed MN cultures (Fig. 4a–c and Online Resource
Fig. S12A). Co-localisation in growth cones was affirmed
by Z-stack analyses. Signal intensity levels of PLS3 and
actin were determined for calculation of Pearson’s coeffi-
cient [48]. However, no overt difference was observable
between control, SMA III and asymptomatic (Online
Resource Fig. S12C, D). Importantly, average fluorescence
mean intensity value of PLS3 per growth cone was sig-
nificantly reduced in SMA III in comparison to
asymptomatic and control MN (Fig. 4d).
In conclusion, co-localization of PLS3 and actin is
similar in asymptomatic, controls and symptomatic growth
cones; however, there may be a significant surplus of PLS3
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in asymptomatic as compared to symptomatic, which may
counteract impaired processes at NMJ level induced by
reduced SMN levels.
Discussion
In this study we successfully applied iPSC technology in
establishing a patient-derived motoneuronal in vitro cell
model with PLS3-discordant mildly affected SMA III and
asymptomatic individuals in comparison to healthy con-
trols and a severe SMA I case. Data revealed cellular
deficits upon SMN depletion at decisive steps of in vitro
MN differentiation. No significant SMN expression dif-
ference was found between asymptomatic and
symptomatic siblings in MN cultures excluding SMN alone
as protective modifier.
Concerning PLS3 expression and its role in MN we
conclude: (1) High PLS3 expression is not required per se
during maturation stage of MNs as reflected by MN
Fig. 4 Confocal microscopy images from growth cones in maturing
MN cultures on d27. a–c Mixed MN cultures from control (a), SMA
III (b) and asymptomatic (c) on d27 immunolabelled with PLS3
(green), actin (red) and MAPT (magenta). Single labelling is pictured
in the left panels and PLS3 and actin staining are overlaid in the right
panels. Growth cones and corresponding fluorescence signal inten-
sities were illustrated in 2.5D profiles (lower left insets). a Control
growth cone shows PLS3 and actin almost equally distributed and
frequently co-localised at the rim. b In SMA III cell line HGK27.13,
presence of PLS3 and actin is demonstrated. c In asymptomatic line
HGK28.9, intense PLS3 expression was visualised particularly in the
rod end and growth cone central domain whereas actin allocated
especially at the edges. Scale bars 10 lm. d Average fluorescence
mean intensity signal value of PLS3 per growth cone was signifi-
cantly diminished in SMA III in comparison to both control and
asymptomatic. In contrast, fluorescence mean intensity value of PLS3
in asymptomatic reached control level hinting at an overall higher
PLS3 amount in asymptomatic growth cones. Growth cones were
analysed from four independent MN differentiation experiments
(n = 4). In total, n = 28 (controls 30 m-r12, 35 m-r1, 51f-s6),
n = 22 (SMA III HGK27.10, HGK27.13) and n = 20 (asymptomatic
HGK21.1, HGK21.8, HGK28.9) growth cones were analysed.
Significance was calculated relative to grouped three healthy controls
(Kruskal–Wallis test, p\ 0.05 = *, p\ 0.01 = **)
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cultures in controls. (2) High PLS3 levels do not protect
against MN loss when SMN levels are dramatically
reduced as in SMA Type I. (3) In asymptomatic individuals
PLS3 is particularly elevated during MN differentiation
peaking in MN cultures (d27) and this correlates with the
unusual elevated expression in lymphoblastoid cell lines
and native blood [14]. (4) PLS3 expression might be sim-
ilarly regulated in MNs and blood but not in other cell
types like fibroblasts. (5) Growth cones of asymptomatic
show an overall higher abundance of PLS3 expression as
compared to symptomatic MNs; the excess of PLS3 might
counteract impaired processes caused by SMN deficiency
at MN and particularly at NMJ level as previously
demonstrated [18].
SMA III and asymptomatic show a SMA
intermediate phenotype in MN cultures
differentiated from iPSCs
iPSC lines from adult fibroblasts of three SMA III patients
and three asymptomatic siblings were generated and vali-
dated by non-integrative SeV technique [40] or retroviral
integration of the four Yamanaka factors [19, 21]. Addi-
tionally, we compared our data to previously published
SMA I and control lines [32, 33]. Furthermore, a stably
expandable self-renewing small molecular neural precursor
cell (smNPC) population [30] was derived and successfully
differentiated into MN cultures yielding valid MN num-
bers. Unlike previous studies [23, 49] our data relied on
two classical MN markers, i.e., ISL1 and HB9 [22]. Three
weeks in vitro maturation resulted in significant decline in
ISL1? as well as HB9? MN numbers in severely affected
SMA I. Likewise, severe SMA mouse models have been
published that develop MNs until birth, followed by mas-
sive MN death in the postnatal period [50–52] as
comparably detected in iPSC-derived SMA I in vitro
models [23, 49]. SMN1-deleted SMA III and asymptomatic
groups exhibited a noticeable yet smaller decrement in
ISL1? and HB9? MN numbers after maturation mirroring
higher SMN2 copy numbers in these groups. In addition,
PLS3 overexpression in asymptomatic did not influence
overall MN survival rate suggesting a PLS3-mediated
protection rather in other parts of the motor circuit than in
MN development itself. Loss of HB9? MNs in control
during maturation likely originated from HB9 downregu-
lation in developing spinal cord [53].
Our data in iPSC-derived SMA I MN models confirmed
previously published data showing marked reduction of
SMN expression and gem counts [23, 47]. SMN expression
level in SMA III and asymptomatic showed mildly reduced
levels in iPSC and smNPCs and no difference in MNs as
compared to controls. Instead SMN gem numbers in both
SMA III and asymptomatic displayed intermediate counts
as compared to controls in all developmental stages. Most
importantly, no statistical differences in SMN expression
and gem counts were found between asymptomatic and
SMA III siblings, excluding SMN as the SMA protective
modifier in asymptomatic siblings. Similar results were
obtained in a recent study [54].
Asymptomatic highly overexpress PLS3 in MN
cultures and particularly in growth cones
as compared to SMA III-affected siblings
Based on transcriptome studies in lymphoblastoid cell lines
and native blood, PLS3 overexpression is regarded as
causative for the asymptomatic phenotype in some SMA
discordant families [14] but not all ([55] and Wirth et al.
unpublished data). In fibroblasts instead, PLS3 showed low
and highly similar expression levels in all four phenotypic
groups, which confirms previous results [14, 55]. In con-
trast to fibroblasts from which all iPSC lines derived, we
found different PLS3 expression levels during MN differ-
entiation stages with asymptomatic presenting around
double as much PLS3 as their symptomatic siblings. PLS3
expression was significantly upregulated in asymptomatic
compared to both male and female controls in MN cultures.
Interestingly, two control male lines showed extremely low
PLS3 expression, suggesting a potential gender-specific
downregulation mechanism and supporting the observation
of a female-specific protective effect in SMA discordant
families [14]. PLS3 level in asymptomatic siblings of
family 2 was 1.9-fold elevated as compared to their SMA
III-affected siblings and highly consistent between two
different clones for each of the four siblings. Instead,
asymptomatic line HGK16 from family 1 did not display a
significant PLS3 upregulation in mixed MN cultures,
although the level was clearly elevated in both iPSCs and
smNPC as compared to the affected sibling HGK13.
Unfortunately, only one clone of this line was available,
making a confirmation in an independent clone impossible.
Importantly, despite lower MN counts in asymptomatic
HGK21 than HGK28 of family 2 the PLS3 expression was
similar and reproducible in all four clones, suggesting an
overall PLS3 upregulation in neuronal cells types in
asymptomatic individuals. This observation can be con-
sidered as particular relevant since there is increasing
evidence that not only MN but also interneurons and pro-
prioceptive inputs on MNs are crucial [56].
Since smNPCs already reveal PLS3 upregulation in
asymptomatic individuals, it might be speculated that
neural lineages and especially MN-specific differentiation
may trigger PLS3 overexpression in asymptomatic patients
by a so far unknown regulatory mechanisms. Concomi-
tantly with our study, Boza-Mora´n et al. found in one of
their discordant families in which PLS3 has previously
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been excluded as genetic modifier that also in iPSC-derived
MN cultures PLS3 is not upregulated in a milder type IV-
affected individual as compared to SMA III-affected sib-
lings [54, 55]. Both studies strengthen the observation that
PLS3 expression in blood mirrors expression in MNs, and
that both tissues may have a similar mechanism for PLS3
expression regulation which remains to be elucidated in
future.
PLS3 expression in iPSCs, smNPCs and MN cultures of
SMA I was comparably high, but no positive effect on MN
survival was observed. This finding is in agreement with (1)
recently published data showing that overexpression of a
PLS3 transgene in a severely affected SMA mouse model
had no impact on MN number or survival [18] and (2) our
previous hypothesis that PLS3 confers full protection only
when a certain amount of SMN is present [13]. Indeed
asymptomatic individuals never carried only two but at least
three SMN2 copies ([14] and Online Resource Tab. S1).
Unlike in zebrafish where decreasing Smn protein
amounts accompanied declining Pls3 protein amounts [57],
data from our in vitro MN system do not suggest a direct
correlation between SMN and PLS3 expression in severely
affected SMA patients since SMA I exhibited high PLS3
expression rates despite overt SMN deficiency. Whether
moderately elevated SMN levels in asymptomatic MN
cultures resulted from possible interaction between SMN
and PLS3 remains to be elucidated.
Multiple studies reported defects in NMJ development
and maintenance, which were therefore regarded as the
hallmark of SMA pathology [58–61]. Interestingly, SMN
levels had little impact on SMA pathology after NMJ
formation and maturation [11]. Since PLS3 overexpression
in SMA mice has shown a major influence on all tested
F-actin dependent processes at the NMJ level and on the
motor activity of these mice [18], our present data strongly
support the view that PLS3 overexpression in MNs can
indeed be a genuine protective SMA modifier.
We previously demonstrated that elevated PLS3 levels
shift the G/F-actin ratio towards more F-actin and change
the dynamics and F-actin dependent functions at MN and
NMJ level in a SMA mouse model overexpressing PLS3
[14]. Moreover, co-localisation of PLS3 with F-actin was
shown in primary murine MNs [14] and in filopodia of
PLS3 overexpressing MEFs [18]. We therefore examined
PLS3 and F-actin expression and distribution by confocal
microscopy analysis in growth cones from human mixed
MN cultures. Indeed, growth cones of controls, SMA III
and asymptomatic siblings were shaped according to pre-
vious descriptions [62] and displayed presence of PLS3 and
actin. MAPT? protrusions denoted axons ending in growth
cones in which actin was located primarily in the peripheral
zone and filopodia-like protrusions [62]. In control growth
cones, an equal PLS3/actin distribution and co-localisation
pattern was found, supporting the conclusion that PLS3
mainly functions in F-actin bundles. In asymptomatic
strong co-localisation of PLS3 and F-actin was mainly
observed at the rim and central domain of the growth
cones. However, co-localisation per se was apparently not
differing between the three phenotype groups since Pear-
son’s coefficient of SMA III and asymptomatic reached the
same medium coefficient values indicating a moderate
PLS3/actin co-localisation in growth cones. However, the
overall average PLS3 fluorescence intensity value, which
supposedly corresponds with the PLS3 amount in a growth
cone was significantly reduced in SMA III while asymp-
tomatic reached control levels. Thus, the absolute PLS3
amount might indeed be increased in asymptomatic growth
cones. This fact might lead to retention of actin filaments
and improved F-actin/PLS3 bundling in asymptomatic
growth cones and thereby extended NMJ stabilisation. This
goes in line with our previous finding that all F-actin
related processes at NMJ level are impaired in SMA mice
and restored by PLS3 overexpression [18]. Still, additional
F-actin-independent roles of PLS3 cannot be excluded
[17]. Since PLS3 has several binding partners involved in
additional processes such as RNA metabolism, translation,
etc. (Wirth lab, unpublished data), abundant PLS3 as found
in asymptomatic siblings might exert the SMA protective
effect by further mechanisms than mere actin-cytoskeleton
stabilisation. Moreover, since the neuronal subtype of the
growth cones was not determined further experiments are
required to substantiate these findings.
We finally conclude that increased PLS3 in asymp-
tomatic SMN1-deleted individuals, who showed also
elevated PLS3 levels in blood, can be considered as a
genuine SMA protective modifier and is a reliable bio-
marker. This opens an avenue for further studies on the
mode of action of PLS3, which might ultimately result in
the development of novel therapies.
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